Insulet Corporation  

(Public, NASDAQ:PODD)   Watch this stock  
Find more results for podd
28.06
+0.35 (1.26%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 27.52 - 28.24
52 week 24.95 - 47.97
Open 27.75
Vol / Avg. 0.00/903,895.00
Mkt cap 1.57B
P/E     -
Div/yield     -
EPS -1.03
Shares 56.75M
Beta 0.96
Inst. own 112%
Aug 5, 2015
Q2 2015 Insulet Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 14, 2015
Insulet Corp Annual Shareholders Meeting (Estimated)
May 13, 2015
Insulet Corp Annual Shareholders Meeting
Apr 30, 2015
Q1 2015 Insulet Corp Earnings Call - Webcast
Apr 30, 2015
Q1 2015 Insulet Corp Earnings Release
Mar 4, 2015
Insulet Corp at Cowen Health Care Conference
Mar 2, 2015
Insulet Corp at Raymond James Institutional Investors Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -19.33% -17.84%
Operating margin -14.10% -12.30%
EBITD margin - -0.03%
Return on average assets -15.62% -17.45%
Return on average equity -57.68% -49.42%
Employees 519 -
CDP Score - -

Address

600 Technology Park Dr Ste 200
BILLERICA, MA 01821-4126
United States - Map
+1-978-6007000 (Phone)
+1-978-6000120 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Insulet Corporation is engaged in the development, manufacturing and sale of OmniPod Insulin Management System (the OmniPod System). The OmniPod System is an insulin infusion system for people with insulin-dependent diabetes. The OmniPod System is a commercially-available insulin infusion system. The OmniPod System features a disposable tubeless OmniPod which is worn on the body, wireless Personal Diabetes Manager (PDM). The OmniPod System features two discreet devices which provides for automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Company has a suite of diabetes management product offerings for insulin dependent patients. The Company provides customers with blood glucose testing supplies, insulin pumps, pump supplies and pharmaceuticals.

Officers and directors

Michael L. Levitz Chief Financial Officer
Age: 41
Bio & Compensation  - Reuters
Daniel J. Levangie President - Insulet Drug Delivery
Age: 64
Bio & Compensation  - Reuters
William Patrick Ryan Chief Operating Officer
Age: 54
Bio & Compensation  - Reuters
Bradley Thomas CFA Executive Vice President - Human Resources & Organizational Development
Age: 57
Bio & Compensation  - Reuters
R. Anthony Anthony Diehl Esq. General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Shacey Petrovic Chief Commercial Officer
Age: 41
Bio & Compensation  - Reuters
Patrick J. Sullivan President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
John A. Fallon Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Charles T. Liamos Director
Age: 55
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 61
Bio & Compensation  - Reuters